% | $
Quotes you view appear here for quick access.

OncoGenex Pharmaceuticals, Inc. Message Board

  • jetmanbash jetmanbash Feb 15, 2011 10:00 PM Flag

    MDVN update:

    Medivation and Astellas announce positive new, long-term follow-up data from phase 1-2 trial (18.63 +0.65)
    Medivation (MDVN) and Astellas Pharma Inc. today announced positive, new, long-term follow-up data from the Phase 1-2 trial of MDV3100 in patients with advanced prostate cancer. MDV3100 is a novel, triple-acting, oral androgen receptor antagonist. These new results showed that MDV3100 continues to show durable antitumor activity as evaluated by median times to prostate-specific antigen progression and radiographic progression. These findings confirm the initial Phase 1-2 results published in The Lancet, in which MDV3100 consistently demonstrated anti-tumor activity in both chemotherapy-naive and post-chemotherapy patients across endpoints, as evaluated by PSA levels, radiographic findings and circulating tumor cell counts.

0.3701-0.0349(-8.62%)Oct 24 4:00 PMEDT